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NEUTRALIZATION OF Bitis parviocula (ETHIOPIAN MOUNTAIN ADDER) VENOM BY THE SOUTH 
AFRICAN INSTITUTE OF MEDICAL RESEARCH (SAIMR) ANTIVENOM
Elda E. SÁNCHEZ(1), Doug HOTLE(2) & Alexis RODRÍGUEZ-ACOSTA(3)
SUMMARY
Background: The Ethiopian mountain adder (Bitis parviocula) is a viperid known only from a few locations in southwestern 
Ethiopia. Methods: a total of 30 µg of B. arietans and B. parviocula venoms were run on a 10-20% Tricine gel. To assay lethality dose 
fifty (LD50), five groups of eight mice for each venom were used. Hemorrhagic activity for crude venom was tested. Fibrinogenolytic 
activity of crude venom was measured using (2.5 mg/mL) of fibrinogen solution and (0.03 mg/mL) of crude venom. Gelatinase 
activity of the venom was tested on a Kodak X-OMAT™ film. Crude venoms of B. parviocula and B. arietans were tested for 
their abilities to affect clotting time, clotting rate and platelet function on whole human blood. Results: The (SAIMR) antivenom 
was confirmed in this study to neutralize the lethal activity of venom from Bitis parviocula. The ED50s of SAIMR antivenom on B. 
parviocula and B. arietans neutralized half of 18.2 and 66.7 mg of venom, respectively. The hemorrhagic activities (MHDs) of B. 
parviocula and B. arietans were 0.88 and 1.7 µg, respectively. Bitis arietans and B. parviocula venoms degradated a and β chains at 
different times. The g chains remained unaffected. Bitis parviocula venom did not exhibit gelatinase activity, while B. arietans had a 
MGD of 6.9 µg. At 3 mg/mL, the crude venoms of B. parviocula and B. arietans did not significantly affect clotting time or clotting 
rate. Conclusions: The SAIMR antivenom is very effective in neutralizing the venom of B. parviocula and should be considered in 
treating envenomations by these snakes. 
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INTRODUCTION
The Ethiopian mountain adder (Bitis parviocula) is a medium sized 
viperid known only from a few locations in southwestern Ethiopia1. 
Until recently only two road-killed specimens and a single live animal 
had been acknowledged and the species remained in relative scientific 
obscurity. In 2007, through an agreement with an exporter, twenty of 
these animals were brought to the United States from Africa10. One of the 
females imported produced young shortly after and this species began to 
make its way into the hobbyist trade as a high-dollar species. 
Given the rarity of this snake, little is known about the composition 
or toxicity of the venom8,14. Indigenous people of southern Ethiopia 
consider this snake highly dangerous14. Epidemiology is virtually 
nonexistent although given the human population in southern Ethiopia; it 
is thought to inflict a reasonable number of bites each year14. The venom 
has traditionally been presumed to be cytotoxic similar to congenerics. 
Some cross-reactivity with polyvalent antivenoms produced against Bitis 
was suspected4. In 2009, an amateur herpetologist in San Antonio, Texas 
was envenomated by a young B. parviocula while attempting to ready the 
animal for shipment. Attending physicians began to administer the South 
African polyvalent antivenom SAIMR (South African Institute of Medical 
Research). However, after ¾ of the initial vial was given the patient 
showed signs of anaphylaxis and the antivenom was stopped at that point. 
Given the negligible dose, it remained unclear if the SAIMR would be 
an effective treatment for this species5,8. In this study, SAIMR was tested 
for its neutralizing ability on the lethal toxicity of B. pariviocula venom. 
The lethal and proteolytic activities of this venom were also compared to 
those of the closely related African Puff adder (Bitis arietans)6.
MATERIALS AND METHODS
Snake collection and husbandry: The B. parviocula were collected in 
SE Ethiopia, Africa (8° 27’ S 1.54’ N 36° 21’ 4.99’E; Fig. 1) and shipped 
to a private individual in the United States. These animals were housed in 
the private collection of Al Coritz. The snakes were held in Vision® snake 
enclosures and kept at 18-25° C. White laboratory mice (Mus musculus) 
were offered as food once every seven days. Fresh water was available ad 
libitum. B. arietans used in this study were collected between Arusha and 
Dar es Salaam, Tanzania, Africa. (5° 02’ 54.91S 37° 3.74684E; Fig. 1). 
SÁNCHEZ, E.E.; HOTLE, D. & RODRÍGUEZ-ACOSTA, A. - Neutralization of Bitis parviocula (Ethiopian Mountain adder) venom by the South African Institute of Medical Research 
(SAIMR) antivenom. Rev. Inst. Med. Trop. Sao Paulo, 53(4): 213-7, 2011.
214
Given that the venom profiles vary in B. arietans across their range10 the 
B. arietans selected for this study originated from a single location. The 
snakes were held as part of the private collection maintained by Douglas 
L. Hotle. The snakes were held in Neodesha® enclosures with an ambient 
temperature of 27 °C. Rodents (Mus musculus and Rattus norvegicus) were 
offered as food once every seven days. Water was available ad libitum. Both 
species were wild caught animals and were considered adults. 
Venom collection: Venom was extracted by allowing the snake to 
bite into a sterile disposable beaker covered with para-film. The venom 
sample was centrifuged 500 g for 10 min at 4 °C, filtered through a 
0.45 µm filter, and frozen at -80 ˚C until lyophilized. 
SDS PAGE: A total of 30 µg of B. arietans and B. parviocula venoms 
were run on a 10-20% Tricine gel at 150 V for 90 min using a SureXCell 
system (Invitrogen). The gel was stained with SimplyBlue (Invitrogen) 
for one hour and distained overnight with 18 megaOhm water. SeeBlue 
Plus2 markers were used as controls.
Lethality Dose (LD50): Five groups of eight mice for each venom 
were housed in cages and observed throughout the quarantine period 
and experiments. The endpoint of lethality of the mice was determined 
after 48 hr. The venom was dissolved in 0.85% saline at the highest test 
dose per mouse. Serial dilutions of 2-fold using saline were made to 
obtain four additional concentrations. All solutions during the experiment 
were stored at 0 °C and warmed to 37 °C just before being injected into 
mice. The lethal toxicity was determined by injecting 0.2 mL of venom 
(containing dosages ranging between 220 to 13.75 µg/mouse) into the tail 
veins of 18-20 g female BALB/c mice. The injections were administered 
using a 1-mL syringe fitted with a 30-gauge, 0.5-inch needle. Saline 
controls were used. The LD50 was calculated by the Spearman-Karber 
method15 (n = 3 ± SD).
Antivenom efficacy dose (ED50): Five groups of eight mice were 
challenged with a mixture of antivenom containing 3 LD50 of venom. 
SAIMR antivenom (Lot #: TO1946; South African Vaccine Producers) 
was diluted with sterile 0.85% saline. A stock venom solution was freshly 
prepared at 0 °C prior to use. For each group of mice, a set concentration 
of venom was mixed with five different antivenom concentrations and 
incubated at 37 ˚C for 30 min. Each mouse was injected into the tail 
vein with 0.2 mL of venom/antivenom mixture in which 3 X LD50s were 
administered per mice. The mice were observed for 48 h and the percent 
survival and ED50 was calculated by the Spearman-Karber method15 
(n = 3 ± SD). 
Hemorrhagic assay: Hemorrhagic activity for crude venom and 
the collected fractions followed the procedure of OMORI-SATOH et 
al. (1972)11. To test for activity, 0.1 mL of each of the fractions was 
injected subcutaneously into the backs of depilated New Zealand rabbits 
(Oryctolagus cuniculus). After 24 h, the rabbits were sacrificed and 
hemorrhagic spots measured (mm). The minimal hemorrhagic dose 
(MHD) was defined as the amount of protein (µg) that causes a 10 mm 
hemorrhagic spot.
Fibrinogenolytic assay: Fibrinogenolytic activity of crude venom 
was measured using a procedure modified from SALAZAR et al. (2007)12. 
Two hundred microliters of fibrinogen solution (2.5 mg/mL) and 100 µL 
of crude venoms (0.03 mg/mL) were incubated together at 37 °C for 
30 min, 1, 2, 4 and 24 h. The samples were run on a 4-12% Bis-Tris 
gels under reducing conditions using a SureXCell system (Invitrogen). 
The gels were stained with SimplyBlue (Invitrogen) for one hour and 
distained with 18 megaOhm water overnight.
Gelatinase assay: Gelatinase activity of the venom fractions was 
tested using a method modified from HUANG & PÉREZ (1980)7. Fifty 
microliters of each venom dilution and fractions were placed on a Kodak 
X-OMAT™ scientific imaging film having a gelatin coating. Hydrolysis 
of gelatin on the X-ray film was determined by washing the film with tap 
water following incubation at 37 °C for four hours in a moist incubator. 
A resulting clear spot on the X-ray film indicated positive activity. The 
assay was repeated three times.
Sonoclot Assay: Crude venoms of B. parviocula and B. arietans were 
tested for their abilities to affect activated clotting time (ACT), clotting 
rate (CR) and platelet function (PF) on whole human blood according 
to the method of SÁNCHEZ et al. (2010)13.
RESULTS
SDS PAGE: Pooled venoms of both B. parviocula and B. arietans 
were compared by SDS gel electrophoresis and 10 visible proteins bands 
were apparent between ~104 and 8 kDa for B. arietans venom while B. 
parviocula had 13 visible bands in the range ~128 and 11 kDa (Fig. 2).
Fig. 1 - Top Map: Collection location of B. parviocula (8° 27’ S 1.54’ N 36° 21’ 4.99’ E; 
elevation 1516 meters). Bottom Map: Collection location of B. arietans collected (5° 02’ 
54. 91’ S 37° 3.74684 E; elevation 1194 meters). Dots indicate approximate locality of 
collected specimens. 
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Lethality Dose (LD50): The LD50s of B. parviocula and B. arietans 
venoms were 1.6 and 1.4 mg/kg body weight, respectively (Table 1).
Antivenom efficacy dose (ED50): The ED50s of SAIMR antivenom 
on B. parviocula and B. arietans were 1/18.2 and 1/66.7, in which 
1 mL of SAIMR antivenom incubated with 18.2 and 66.7 mg of venom, 
respectively can protect 50% of the population (Table 1). 
Hemorrhagic assay: The hemorrhagic activities (MHDs) of B. 
parviocula and B. arietans were 0.88 and 1.7 µg, respectively. Western 
diamondback rattlesnake (Crotalus atrox) venom was used as a control 
giving a MHD of 2.5 µg (Table 1).
Fibrinogenolytic assay: Bitis arietans was able to completely 
degrade the a chain of human fibrinogen by 30 min while B. parviocula 
took four hours to completely degrade the a chain (Table 1). However, 
B. parviocula venom was able to degrade the β chain much faster (four 
hours) than B. arietans (24 h). The venom of Crotalus atrox was used 
as a control and had activity similar to B. parviocula venom in the 
fibrinogenolytic assay. Neither venom affected the g chain (Fig. 3).
Gelatinase assay: Bitis parviocula venom did not exhibit gelatinase 
activity, while B. arietans had a MGD of 6.9 µg (Table 1). 
Sonoclot assay: The ACTs and CRs were slightly delayed for the 
venoms of B. arietans and B. parviocula as compared to the normal blood 
control (Table 1, Fig. 4), while the PFs for both Bitis ssp. venoms were 
significantly affected, meaning that these venoms had a strong effect on 
blood platelets. 
Fig. 2 - A SDS gel electrophoresis of B. arietans and B. parviocula venoms. A total of 30 
µg of protein of venoms was run on a 10-20% Tricine gel under non-reducing conditions at 
150 V for 90 min using a SureXCell system. Lanes: 1) SeeBlue Plus2 markers; 2) B. arietans 
3) B. parviocula .
Table 1
Proteolytic and lethal activities of Bitis arietans and B. parviocula venoms
Venoms
MHD
(µg)
MGD
(µg)
Fibrinogenolytic
30 min
4 h
24 h
a, β, g
LD50
(mg/kg)
ED50
(mL/mg)†
Sonoclot‡
ACT, CR, PF
Bitis arietans 1.7±0.5 6.9±1
+, -, -
+, -, -
+, +, -
1.35 1/67 230±15, 21±10, 0±0.1
Bitis parviocula 0.88±0.6 NA
-, -, -
+, +, -
+, +, -
1.56 1/18 280±10, 13±5, 0±0.1
MHD: The minimal hemorrhagic dose is the minimal amount of venom that will cause a 10 mm hemorrhagic spot according to the method of OMORI-SATOH et al. 
(1972)11. MGD: The minimal gelatinase dose is the minimal amount of venom that will cause a clearing area on an X-ray film according to the method of HUANG & 
PEREZ (1980)7. NA: No activity. LD50: The lethal dose 50 is the amount of venom that will kill 50% of a population according to the method of SÁNCHEZ et al. (2010)13.
ED50: The effective dose 50 is the titer of anitvenom to venom that will protect 50% of the population according to the method of SÁNCHEZ et al. (2010)13. Antive-
nom-SAIMR Polyvalent Snake Antivenom. South African Vaccine Producers (PTY) LTD. 1 Modderfontien Rd. Edenvale, Gauteng Lot # TO1946. †: mL/mg: 1 mL 
of antivenom incubated with venom (mg) protects 50% of the population. +: degradation, -: no degradation. Human fibrinogen was used according to the method of 
SALAZAR et al. (2007)12. ‡ACT: activated clot time (s); CR: clot rate (clot signals/min); PF: platelet function. Normal blood control ACT: 189±15, CR: 30±5, and 
PF: 2.0±1.5. A Sonoclot® Coagulation & Platelet Function Analyzer was used (SIENCO®, Inc., Arvada, CO). The method of SÁNCHEZ et al., (2010)13 was followed.
Fig. 3 - Fibrinogenolytic activity of B. arietans (Ba), B. parviocula (Bp) and Crotalus atrox 
(Ca) venoms. Two hundred microliters of fibrinogen (2.5 mg/mL) was incubated with 100 µL 
of venom sample (0.03 mg/mL) and incubated at 30 min, 2, 4 and 24 h. The samples were run 
on a 4-12% Bis-Tris gel under reducing conditions using a SureXCell system (Invitrogen). 
The gel was stained with SimplyBlue for 1 h and distained in 18 mega ohm water overnight.
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DISCUSSION
Bitis parviocula has a close taxonomic relationship with other 
Macrocerastes such as the Puff adder (Bitis arietans), Gaboon vipers 
(Bitis gabonica and B. rhinoceros), Rhinoceros viper (Bitis nasicornis) 
among others1; and therefore, the presumption was that antivenoms 
traditionally used for other Bitis would have cross-reactivity against 
envenomation from B. parviocula8,14. However, cross-reactivity does 
not always equal cross-protection3. In many cases usage of antivenoms 
against untested species can be dangerous, or at the least non-beneficial8. 
The addition of the B. parviocula into many private and zoological 
collections increases the likelihood of accidental envenomations by this 
species. Emergency physicians and snakebite consultants are increasingly 
faced with treating venomous snakebites inflicted by non-native snakes10. 
An understanding of the cross-protection of specific antivenoms is crucial 
in the treatment of these emergencies. 
Prior to antivenom neutralization, the venoms of B. parviocula and 
B. arietans were compared by SDS electrophoresis in which there were 
differences in the quantity of proteins in that B. parviocula had three 
more proteins bands than B. arietans (Fig. 2). The venoms were also 
compared with a series of biological assays. 
These venoms were analyzed using a Sonoclot® Coagulation 
& Platelet Function Analyzer, in which the measurements are based 
on the detection of viscoelastic changes of whole blood or plasma6. 
The Sonoclot® provides qualitative (Sonoclot Signature graph) 
and quantitative (ACT, CR and PF) results on the entire hemostasis 
process. The activated clotting time (ACT) is the time in which fibrin 
formation begins, the clotting rate (CR) is the kinetic measurement of 
fibrin formation and clot development, which is the maximum slope 
of the Sonoclot Signature during initial fibrin polymerization and clot 
development, and platelet function (PF) is obtained from the timing and 
quality of the clot retraction. The values for PF range from 0-5, where 
0 represents no clot retraction. A PF higher than 1 represents normal 
clot retraction and varies from patient to patient. A normal PF contains 
a sharp peak in the Sonoclot Signature after fibrin formation, as seen 
on the control sample in Figure 4. The ACTs and CRs were slightly 
delayed for the venoms of B. arietans and B. parviocula as compared to 
the normal blood control (Table 1, Fig. 4), while the PFs for both Bitis 
venoms were significantly affected, meaning that these venoms had a 
strong effect on blood platelets. Whether there are components in these 
venoms that bind to the receptors (e.g. aIIbβ3) of platelets thus inhibiting 
platelet aggregation, or if the venom components degrade the receptors or 
the platelets themselves is yet to be determined. Crotalus atrox venom, 
used as a control, rendered the blood sample unclottable (Fig. 4). 
The ability to degrade human fibrinogen was also tested. Bitis arietans 
was able to completely degrade the a chain of human fibrinogen by 
30 min while B. parviocula took 4 h to completely degrade the a chain 
(Table 1; Fig. 3). However, B. parviocula venom was able to degrade the 
β chain much faster (4 h) than B. arietans (24 h). The venom of Crotalus 
atrox was used as a control and had activity similar to B. parviocula 
venom in the fibrinogenolytic assay. Neither venom affected the 
g chain.
Both Bitis venoms were very hemorrhagic with minimal hemorrhagic 
doses (MHDs) for B. arietans and B. parviocula venoms of 1.7 and 
0.87 µg, respectively (Table 1), signifying B. parviocula to be twice as 
hemorraghic. The hemorrhagic activity of B. arietans is comparable to 
the hemorrhagic activity of C. atrox and C. oreganus helleri venoms 
(~2.5-2.3 µg), while that of B. parviocula venom hemorrhagic activity 
is comparable to the venoms of Crotalus viridis (~0.7 µg)13. In contrast, 
B. parviocula did not contain gelatinase activity when tested on an X-ray 
film, while B. arietans had a minimal gelatinase dose (MGD) of 6.9 µg 
(Table 1). These results could imply the absence or low abundance of 
collagenases in the venom of B. parviocula.
The LD50 for B. arietans and B. parviocula venoms were 1.35 and 
1.56 mg/kg, respectively, and the SAIMR antivenom was capable of 
neutralizing both venoms quite well (Table 1). The ED50 for the SAIMR 
antivenom against B. arietans was 1/67, which translates to 66 mg 
of venom incubated with 1 mL of antivenom can protect 50% of the 
BALB/c mouse population. The ED50 with B. parviocula was 1/18, thus 
the SAIMR antivenom neutralizes ~ 4 times more venom of B. arietans, 
which is not surprising since this venom is used in the production of this 
antivenom (Table 1). Even though SAIMR only protected 50% of the 
population with less B. parviocula venom, it still protected significantly 
considering that this venom was not used for the manufacture of the 
antivenom. According to MALLOW et al. (2003)9, the average B. arietans 
venom yield ranges between 100-350 mg, with a maximum of 750 mg, 
while the average venom yield for B. parviocula is 100 mg (personal 
communication by Doug Hotle). Therefore, theoretically, two to three 
10 mL vials of SAIMR antivenom can neutralize the maximum amount 
of venom from a single extraction of either snake. It is apparent that 
there exist components in B. parviocula venom that are not as easily 
neutralized as those of B. arietans. It is well documented that variation 
in venom composition exists among Bitis species2.
Nonetheless, in this study we have shown that the South African 
polyvalent antivenom SAIMR did produce paraspecific neutralization 
of lethality with B. parviocula venom in vivo, and should be considered 
in emergency treatment. 
Fig. 4 - The effects of activated clot time (ACT), clot rate (CR) and platelet function (PF) 
by Bitis venoms. A total of 10 µL of venom sample (3 mg/mL) was added to glass bead 
activated cuvettes (gbACT+ KIT) containing 350 µL of 10% citrated whole human blood. 
The ACT, CR and PF were analyzed on a Sienco Sonoclot® Analyzer System. Red: normal 
blood control, blue: B. arietans venom + blood, green: B. parviocula venom + blood, and 
black: C. atrox venom + blood.
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RESUMO
Neutralização do veneno de Bitis parviocula (serpente da 
Montanha da Etiópia) pelo antiveneno do Instituto Africano de 
Pesquisa Médica (SAIMR) 
Background: Serpente das Montanhas da Etiópia (Bitis parviocula) 
é um viperídeo conhecido somente em poucas localizações do sudoeste 
da Etiópia. Métodos: Um total de 30 µg de veneno de B. arietans e 
B. parviocula foram corridos em gel de 10 a 20% de tricina. Para se 
estabelecer a quinquagésima dose de letalidade (LD50) foram usados cinco 
grupos de oito camundongos para cada veneno. A atividade hemorrágica 
para o veneno cru foi testada. A atividade fibrogenolítica do veneno cru 
foi medida usando 2,5 mg/mL de solução de fibrinogênio e 0,03 mg/mL 
de veneno cru. A atividade de gelatinase do veneno foi testada em um 
filme KODAK X-OMATTM. Venenos crus de B. parviocula e B. arietans 
foram testados no que diz respeito à sua capacidade de afetar o tempo de 
coagulação, a velocidade de coagulação e a função plaquetogênica em 
sangue humano total. Resultado: o antiveneno SAIMR foi confirmado 
neste estudo no que diz respeito à neutralização da atividade letal 
do veneno de Bitis parviocula. ED50s do antiveneno SAIMR sobre 
a B. parviocula e B. arietans neutralizou metade de 18,2 e 66,7 mg 
respectivamente do veneno. As atividades hemorrágicas (MHDs) de B. 
parviocula e B. arietans foram respectivamente 0,88 e 1,7 µg. Os venenos 
de B. arietans e B. parviocula degradaram cadeias a e β em tempos 
diferentes. A cadeia g permaneceu não afetada. O veneno da B. parviocula 
não mostrou atividade de gelatinase, enquanto o de B. arietans teve um 
MGD de 6,9 µg. A nível de 3 mg/mL os venenos crus de B. parviocula 
e B. arietans não afetaram significantemente o tempo e a velocidade de 
coagulação. Conclusões: O antiveneno SAIMR é bastante efetivo para 
neutralizar o veneno da B. parviocula e deveria ser considerado para o 
tratamento de envenenamentos por estas serpentes. 
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